Interferential Electrical Stimulation and Vasodilatation in Healthy Individuals

Interferential Electrical Stimulation Improves Peripheral Vasodilatation in Healthy Individuals: A Randomized Crossover Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01450371

Acronym

InterM

Enrollment

Registered

2011-10-12

Start date

2011-07-31

Completion date

2012-10-31

Last updated

2013-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decreased Vascular Flow

Keywords

Autonomic Nervous System, Neuromodulation, Blood flow control, Exercise

Brief summary

Interferential electrical stimulation (IES) increases local blood flow. It is not known whether increases in blood flow may be caused by inhibition of sympathetic activity, mediated by muscle metaboreflex activity. The purpose of this study was to evaluate the effect of IES on metaboreflex activation in healthy subjects.

Detailed description

The study sample consisted of 11 healthy young individuals. All subjects were non-smokers, non-obese and free of any signs or symptoms of disease, as revealed by medical history, physical examination and electrocardiogram at rest and during cardiopulmonary exercise testing. Exclusion criteria were pregnancy, breast-feeding, alcohol or drug abuse, and any medication with potential effects on cardiovascular variables. Subjects were asked not to drink caffeine-containing drinks or exercise for at least 12 and 48 hours, respectively, before the experimental protocols.

Interventions

DEVICEInterferential

The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).

DEVICEInterferential Placebo

The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects are non-smokers * non-obese * and free of any signs or symptoms of disease

Exclusion criteria

* Pregnancy * breast-feeding * alcohol or drug abuse * medication with potential effects on cardiovascular variables

Design outcomes

Primary

Measure	Time frame	Description
Muscle Metaboreflex Reflex	Participants will be followed for the duration of metaboreflex activity (up to 30 minutes)	Calf blood flow

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026